Rigel Pharmaceuticals Inc (RIGL)

2.29
NASDAQ : Health Care
Prev Close 2.34
Day Low/High 2.22 / 2.37
52 Wk Low/High 1.88 / 3.68
Avg Volume 418.10K
Exchange NASDAQ
Shares Outstanding 92.14M
Market Cap 215.62M
EPS -0.60
P/E Ratio 3.90
Div & Yield N.A. (N.A)

Latest News

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer

Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program

Short Interest In Rigel Pharmaceuticals Makes 14.2% Move

Short Interest In Rigel Pharmaceuticals Makes 14.2% Move

The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, which shows a 355,726 share increase in total short interest for Rigel Pharmaceuticals Inc , to 2,855,027, an increase of 14.23% since 05/29/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Rigel Pharmaceuticals (RIGL) Strong On High Relative Volume Today

Rigel Pharmaceuticals (RIGL) Strong On High Relative Volume Today

Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a strong on high relative volume candidate

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 11.3% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.61/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 15 cents.

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.

Rigel And Bristol-Myers Squibb Announce Research And Development Collaboration For TGF Beta Receptor Kinase Inhibitors For Use In Immuno-Oncology Related Indications

Rigel And Bristol-Myers Squibb Announce Research And Development Collaboration For TGF Beta Receptor Kinase Inhibitors For Use In Immuno-Oncology Related Indications

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of...

Short Interest Moves 40.6% Lower For RIGL

Short Interest Moves 40.6% Lower For RIGL

The most recent short interest data has been released by the NASDAQ for the 12/31/2014 settlement date, which shows a 1,029,643 share decrease in total short interest for Rigel Pharmaceuticals Inc , to 1,508,837, a decrease of 40.56% since 12/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Rigel To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Rigel To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Earns $5.75M Milestone from AstraZeneca for Asthma Program

Rigel Announces Executive Management Changes

Rigel Announces Executive Management Changes

James M. Gower Retires, Raul Rodriguez Named CEO and Appointed to the Board, Gary Lyons Named Chairman

Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today

Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today

Rigel Pharmaceuticals (RIGL) shares are down after the company announced that it was stopping the testing of its dry eye disease treatment.

R348 Did Not Meet Endpoints In Phase 2 Dry Eye Study

R348 Did Not Meet Endpoints In Phase 2 Dry Eye Study

Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy

First Week of RIGL March 2015 Options Trading

First Week of RIGL March 2015 Options Trading

Investors in Rigel Pharmaceuticals Inc saw new options become available this week, for the March 2015 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 226 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.